These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24055046)

  • 21. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
    Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
    J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1
    Park MS; Park HJ; An YJ; Choi JH; Cha G; Lee HJ; Park SJ; Dewang PM; Kim DK
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):702-712. PubMed ID: 32164459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
    Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
    Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis for specificity of TGFβ family receptor small molecule inhibitors.
    Ogunjimi AA; Zeqiraj E; Ceccarelli DF; Sicheri F; Wrana JL; David L
    Cell Signal; 2012 Feb; 24(2):476-483. PubMed ID: 21983015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of N-(3-fluorobenzyl)-4-(1-(methyl-d
    Kang BN; Kang HJ; Kim S; Lee J; Lee J; Jeong HJ; Jeon S; Shin Y; Yoon C; Han C; Seo J; Yun J
    Bioorg Med Chem Lett; 2023 Apr; 85():129205. PubMed ID: 36858078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor beta2 regulates growth and differentiation of pulp cells via ALK5/Smad2/3.
    Tai TF; Chan CP; Lin CC; Chen LI; Jeng JH; Chang MC
    J Endod; 2008 Apr; 34(4):427-32. PubMed ID: 18358889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological evaluation of novel 2-pyridinyl-[1,2,4]triazoles as inhibitors of transforming growth factor beta1 type 1 receptor.
    Kim DK; Kim J; Park HJ
    Bioorg Med Chem; 2004 May; 12(9):2013-20. PubMed ID: 15080905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel ALK5 inhibitor TP0427736 reduces TGF-β　induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
    Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
    Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of novel 2-pyridinyl-[1,2,3]triazoles as inhibitors of transforming growth factor beta 1 type 1 receptor.
    Kim DK; Kim J; Park HJ
    Bioorg Med Chem Lett; 2004 May; 14(10):2401-5. PubMed ID: 15109621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
    Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
    J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
    Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
    Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.
    Terashima H; Kato M; Yasumo H; Tsuchida H; Mizuno M; Sada T
    Am J Physiol Renal Physiol; 2010 Oct; 299(4):F792-801. PubMed ID: 20660018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment.
    Almeida MO; Trossini GH; Maltarollo VG; Silva Dda C; Honorio KM
    J Biomol Struct Dyn; 2016 Sep; 34(9):2045-53. PubMed ID: 26524124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
    Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
    Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human xylosyltransferase-I - a new marker for myofibroblast differentiation in skin fibrosis.
    Faust I; Roch C; Kuhn J; Prante C; Knabbe C; Hendig D
    Biochem Biophys Res Commun; 2013 Jul; 436(3):449-54. PubMed ID: 23747722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGF-beta inhibits CYP17 transcription in H295R cells acting via activin receptor-like kinase 5.
    Derebecka-Holysz N; Lehmann TP; Holysz M; Trzeciak WH
    Endocr Res; 2009; 34(3):68-79. PubMed ID: 19701832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.